Viewing nowCombinationJanumet Tablet 50/500 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.

MFDS item code 200713008 · Approved 2007.12.04 · Insurance code 643309600
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes manage their blood sugar levels more effectively when used in conjunction with diet and exercise therapy. The combination of sitagliptin and metformin assists in stabilizing blood sugar levels, showing positive effects in diabetes management. Therefore, this medication is used to improve blood sugar control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic medication whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined taking the patient's blood glucose level and existing dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is composed of sitagliptin and metformin and is used in the treatment of diabetes. The sitagliptin component can rarely cause severe allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, use should be discontinued immediately. Additionally, inflammation of the pancreas, known as pancreatitis, may occur, so if symptoms such as abdominal pain, nausea, or vomiting arise, immediate consultation with a doctor is necessary. The metformin component can cause a rare but serious metabolic disorder called lactic acidosis, and it should not be used in patients with poor kidney function or liver disease. Patients with reduced kidney function, serious infections, dehydration, heart failure, etc., should not be administered this medication, and it should be temporarily discontinued during certain periods before and after surgery. This medication is not administered to pregnant or breastfeeding women or children under 18 years of age as safety has not been established. During treatment with this medication, kidney function and blood tests, as well as vitamin B12 levels, should be monitored regularly. If sudden fatigue, muscle pain, difficulty breathing, or abdominal pain occur, a doctor should be informed immediately. The risk of hypoglycemia may increase when taken in conjunction with other medications that lower blood sugar, so attention should be paid to symptoms and medication dosage adjustments may be necessary. Alcohol consumption may elevate the risk of lactic acidosis, so drinking should be avoided while taking this medication. It is advisable to consult with a doctor about temporarily discontinuing medication prior to surgery or radiological procedures with contrast agents. This medication may cause side effects such as diarrhea, nausea, headache, upper respiratory tract infections, so if symptoms are severe, consultation with healthcare professionals is necessary.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is also advisable to store it at room temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the medication's efficacy for a longer period.
An oval film-coated tablet of bright pink color, engraved with 575 on one side
56 tablets (14 tablets/PTPx4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.